Early Breast Cancer Clinical Trial
Official title:
A Multicenter, Double-blind, Randomized Controlled Phase II Clinical Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity
Verified date | November 2023 |
Source | Henan Cancer Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Taxane-induced peripheral neuropathy (TIPN) caused by paclitaxel is a dose-limiting toxicity. The main symptoms of discomfort are numbness, tingling, and burning sensations in the glove-sock-like distribution of the limbs. At present, there are few effective methods for clinical treatment of TIPN, and there is no widely agreed consensus on effective treatment in the world. Therefore, it is of great clinical significance and practical value to carry out clinical research to explore drugs to relieve TIPN.
Status | Completed |
Enrollment | 159 |
Est. completion date | April 21, 2022 |
Est. primary completion date | April 21, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Female patients diagnosed with early breast cancer by histology; 2. Age =18 years old and =75 years old 3. It is expected that the standard chemotherapy regimen containing albumin paclitaxel will be used in the adjuvant / neo-adjuvant chemotherapy regimen. The standard scheme includes: a. Albumin paclitaxel adopts a single-week regimen, 125-150mg / m2 for 12 weeks; b. Albumin paclitaxel Take a 3-week regimen, 260 mg / m2, for a total of 4 cycles. The plan must not contain platinum and other types of purple shirt drugs; 4. ECOG score of the patient is =1; 5. Expected survival time = 3 months; 6. The function level of main organs must meet the following requirements (no blood transfusion and no use of leukocyte or platelet rising drugs within 2 weeks before screening) Blood routine: neutrophil (ANC) = 1.5x 109 / L; platelet (PLT) = 90x109 / L; hemoglobin (Hb) = 90g / L Blood biochemical total bilirubin (TBIL) = 1.5xULN; alanine aminotransferase (AST) and aspartate aminotransferase (AST) not exceeding 2 × ULN; blood urea nitrogen (BUN) and creatinine (CR) below 1.5 × ULN; 7. FACT-Ntx score is 44 points in the screening period 8. Sign the informed consent. Exclusion Criteria: 1. There are any toxic events of the peripheral nervous system before enrollment, including: FACT-Ntx subscale score <44; = 1 level of peripheral toxicity according to the CTCAE version 4.0 scale; all other pathological symptoms or diseases may affect Assessment of adverse neurotoxic effects; 2. Patients receiving other medications may cause similar adverse neurotoxic effects within 4 weeks before treatment with this regimen, or they may also receive neurotoxic medications at the same time. Including paclitaxel or analogues; vinca alkaloids or analogues; platinums or analogues; cytarabine, thalidomide, bortezomib or cabazine; other drugs or treatments may cause peripheral neurotoxicity; 3. Patients with poor overall condition and ECOG score> 1; 4. pregnant or lactating women; 5. Patients who also suffer from other neurological abnormalities cannot accurately record the occurrence and severity of neurotoxicity; 6. The patient is known to be allergic to the test drug or excipient ingredients of these products; 7. Patients with hereditary abnormalities of glucose and lipid metabolism (gangliopathies, such as idiopathic and retinopathy of triad families); 8. Patients not suitable for ganglioside treatment; 9. Patients with severe concurrent diseases may endanger safety and interfere with scheduled treatment, or the combination of diseases may affect the completion of the study, depending on the judgment of the investigator. 10. Patients with a clear history of neurological or mental disorders, including epilepsy or dementia. |
Country | Name | City | State |
---|---|---|---|
China | Henan Cancer Hospital | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
Henan Cancer Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functional Assessment of Cancer Treatment Neurotoxicity Scale (FACT-Ntx)score | FACT-Ntx scale score 2 weeks after 4 cycles of albumin-bound paclitaxel chemotherapy. (The FACT-Ntx subscale includes 11 items, each of which is divided into 5 scoring levels: 0, 1, 2, 3, 4, and a total score of 44. Higher scores indicate lower side effects). The scale is graded 0-4. A low score indicates a good effect. | 2 weeks after 4 cycles of albumin-bound paclitaxel chemotherapy | |
Secondary | CTCAE Version 4.0 score | neurotoxicity evaluated by NCI-CTCAE version 4.0 grading scale which classified symptoms as grade 0, 1, 2, 3, or 4. Higher scores indicate more severe neurotoxicity.
The NCI-CTCAE version 4.0 assessments were performed at 2 weeks after each course of chemotherapy. Additional long-term assessments were performed at 3 months, 6 months and 1 year after the end of chemotherapy. |
1 month Day 1 of Week 1 to 1 year after the last course of chemotherapy | |
Secondary | Functional Assessment of Cancer Treatment Neurotoxicity Scale (FACT-Ntx)score | The scale is graded 0-4. A low score indicates a good effect. | 3 months, 6 months, and 12 months after 4 cycles of chemotherapy | |
Secondary | functional assesment of cancer therapy-taxane (FACT-Taxane)score | Compare FACT-Taxane outcome in treatment vs placebo groups at 2 weeks after 4 cycles of chemotherapy. Lower scores indicate worse functional status. Total possible range is 0 to 64.The paclitaxel therapeutic function assessment scale is mainly used to assess baseline peripheral neurotoxicity, and a lower score indicates less neurotoxicity. | 2 weeks after 4 cycles of albumin-bound paclitaxel chemotherapy | |
Secondary | Functional Assessment of Cancer Therapy-General (FACT-G)score | Compare FACT-G outcome in treatment vs placebo groups at 2 weeks after 4 cycles of chemotherapy. Lower scores indicate worse functional status. Total possible range is 0 to 128.The low score of the cancer patients' quality of life scale indicates that the patients' quality of life is better. | 2 weeks after 4 cycles of albumin-bound paclitaxel chemotherapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04538833 -
GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel
|
Phase 2 | |
Completed |
NCT04436744 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
|
Phase 2 | |
Completed |
NCT02187744 -
A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)
|
Phase 3 | |
Terminated |
NCT01155063 -
Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
|
N/A | |
Recruiting |
NCT03949634 -
Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin(PLD)
|
Phase 3 | |
Active, not recruiting |
NCT05730647 -
Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients
|
||
Terminated |
NCT01919229 -
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
|
Phase 2 | |
Active, not recruiting |
NCT04293393 -
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
|
Phase 2 | |
Completed |
NCT00713141 -
Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer
|
N/A | |
Recruiting |
NCT06341894 -
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06404736 -
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06404463 -
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06435104 -
Aromatherapy in the Treatment of Early Breast Cancer
|
Phase 2 | |
Recruiting |
NCT03520894 -
Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer
|
N/A | |
Completed |
NCT03786198 -
Activity Program During Aromatase Inhibitor Therapy
|
N/A | |
Completed |
NCT01613352 -
Feasibility of Ambulatory Surgery for Early Breast Cancer
|
N/A | |
Completed |
NCT02738970 -
A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)
|
Phase 1 | |
Recruiting |
NCT01792726 -
A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.
|
N/A | |
Completed |
NCT00323479 -
Arthralgia During Anastrozole Therapy for Breast Cancer
|
Phase 4 | |
Completed |
NCT03493854 -
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
|
Phase 3 |